Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel Free ABDX Stock Alerts

Abingdon Health (ABDX) Competitors

Abingdon Health logo
GBX 10.04 -0.46 (-4.38%)
As of 08/14/2026 11:11 AM Eastern
Compare

ABDX vs. GDR, YGEN, AGL, GENI, and PRM

Should you buy Abingdon Health stock or one of its competitors? Abingdon Health's main competitors and comparable companies include genedrive (GDR), Yourgene Health (YGEN), ANGLE (AGL), GENinCode (GENI), and Proteome Sciences (PRM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Abingdon Health compare to genedrive?

Abingdon Health (LON:ABDX) and genedrive (LON:GDR) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Abingdon Health has higher revenue and earnings than genedrive. Abingdon Health is trading at a lower price-to-earnings ratio than genedrive, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abingdon Health£9.57M2.63-£796.37K-£0.81N/A
genedrive£929K20.17-£21.22M-£0.79N/A

In the previous week, genedrive had 1 more articles in the media than Abingdon Health. MarketBeat recorded 1 mentions for genedrive and 0 mentions for Abingdon Health. Abingdon Health's average media sentiment score of 0.00 equaled genedrive'saverage media sentiment score.

Company Overall Sentiment
Abingdon Health Neutral
genedrive Neutral

Abingdon Health has a beta of 0.16, suggesting that its share price is 84% less volatile than the broader market. Comparatively, genedrive has a beta of 0.989, suggesting that its share price is 1% less volatile than the broader market.

3.7% of Abingdon Health shares are held by institutional investors. Comparatively, 0.1% of genedrive shares are held by institutional investors. 8.0% of Abingdon Health shares are held by insiders. Comparatively, 29.0% of genedrive shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Abingdon Health has a net margin of -33.88% compared to genedrive's net margin of -500.75%. Abingdon Health's return on equity of -55.91% beat genedrive's return on equity.

Company Net Margins Return on Equity Return on Assets
Abingdon Health-33.88% -55.91% -17.93%
genedrive -500.75%-1,044.57%-74.09%

Summary

Abingdon Health and genedrive tied by winning 6 of the 12 factors compared between the two stocks.

How does Abingdon Health compare to Yourgene Health?

Yourgene Health (LON:YGEN) and Abingdon Health (LON:ABDX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

Yourgene Health has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, Abingdon Health has a beta of 0.16, meaning that its stock price is 84% less volatile than the broader market.

In the previous week, Yourgene Health's average media sentiment score of 0.00 equaled Abingdon Health'saverage media sentiment score.

Company Overall Sentiment
Yourgene Health Neutral
Abingdon Health Neutral

Abingdon Health has lower revenue, but higher earnings than Yourgene Health. Abingdon Health is trading at a lower price-to-earnings ratio than Yourgene Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Yourgene Health£29.67M0.00-£8.17M-£0.01N/A
Abingdon Health£9.57M2.63-£796.37K-£0.81N/A

23.3% of Yourgene Health shares are held by institutional investors. Comparatively, 3.7% of Abingdon Health shares are held by institutional investors. 64.4% of Yourgene Health shares are held by company insiders. Comparatively, 8.0% of Abingdon Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Yourgene Health has a net margin of -27.55% compared to Abingdon Health's net margin of -33.88%. Yourgene Health's return on equity of -27.06% beat Abingdon Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Yourgene Health-27.55% -27.06% -6.71%
Abingdon Health -33.88%-55.91%-17.93%

Summary

Yourgene Health beats Abingdon Health on 8 of the 10 factors compared between the two stocks.

How does Abingdon Health compare to ANGLE?

Abingdon Health (LON:ABDX) and ANGLE (LON:AGL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Abingdon Health has higher revenue and earnings than ANGLE. Abingdon Health is trading at a lower price-to-earnings ratio than ANGLE, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abingdon Health£9.57M2.63-£796.37K-£0.81N/A
ANGLE£2.62M2.89-£21.76M-£4.80N/A

3.7% of Abingdon Health shares are owned by institutional investors. Comparatively, 17.5% of ANGLE shares are owned by institutional investors. 8.0% of Abingdon Health shares are owned by company insiders. Comparatively, 2.7% of ANGLE shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Abingdon Health has a net margin of -33.88% compared to ANGLE's net margin of -1,444.04%. Abingdon Health's return on equity of -55.91% beat ANGLE's return on equity.

Company Net Margins Return on Equity Return on Assets
Abingdon Health-33.88% -55.91% -17.93%
ANGLE -1,444.04%-191.36%-29.89%

In the previous week, ANGLE had 1 more articles in the media than Abingdon Health. MarketBeat recorded 1 mentions for ANGLE and 0 mentions for Abingdon Health. Abingdon Health's average media sentiment score of 0.00 beat ANGLE's score of -0.08 indicating that Abingdon Health is being referred to more favorably in the media.

Company Overall Sentiment
Abingdon Health Neutral
ANGLE Neutral

Abingdon Health has a beta of 0.16, suggesting that its share price is 84% less volatile than the broader market. Comparatively, ANGLE has a beta of 0.22, suggesting that its share price is 78% less volatile than the broader market.

Summary

Abingdon Health beats ANGLE on 8 of the 13 factors compared between the two stocks.

How does Abingdon Health compare to GENinCode?

Abingdon Health (LON:ABDX) and GENinCode (LON:GENI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

In the previous week, Abingdon Health's average media sentiment score of 0.00 equaled GENinCode'saverage media sentiment score.

Company Overall Sentiment
Abingdon Health Neutral
GENinCode Neutral

Abingdon Health has a net margin of -33.88% compared to GENinCode's net margin of -185.47%. Abingdon Health's return on equity of -55.91% beat GENinCode's return on equity.

Company Net Margins Return on Equity Return on Assets
Abingdon Health-33.88% -55.91% -17.93%
GENinCode -185.47%-409.40%-63.99%

Abingdon Health has higher revenue and earnings than GENinCode. Abingdon Health is trading at a lower price-to-earnings ratio than GENinCode, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abingdon Health£9.57M2.63-£796.37K-£0.81N/A
GENinCode£3.08M2.18-£6.10M-£2.08N/A

Abingdon Health has a beta of 0.16, suggesting that its share price is 84% less volatile than the broader market. Comparatively, GENinCode has a beta of 0.557, suggesting that its share price is 44% less volatile than the broader market.

3.7% of Abingdon Health shares are held by institutional investors. Comparatively, 11.4% of GENinCode shares are held by institutional investors. 8.0% of Abingdon Health shares are held by insiders. Comparatively, 8.4% of GENinCode shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Abingdon Health beats GENinCode on 7 of the 11 factors compared between the two stocks.

How does Abingdon Health compare to Proteome Sciences?

Abingdon Health (LON:ABDX) and Proteome Sciences (LON:PRM) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

In the previous week, Abingdon Health's average media sentiment score of 0.00 equaled Proteome Sciences'average media sentiment score.

Company Overall Sentiment
Abingdon Health Neutral
Proteome Sciences Neutral

Abingdon Health has a net margin of -33.88% compared to Proteome Sciences' net margin of -81.50%. Proteome Sciences' return on equity of 33.80% beat Abingdon Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Abingdon Health-33.88% -55.91% -17.93%
Proteome Sciences -81.50%33.80%-19.25%

Abingdon Health has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market. Comparatively, Proteome Sciences has a beta of 0.148, suggesting that its stock price is 85% less volatile than the broader market.

3.7% of Abingdon Health shares are owned by institutional investors. Comparatively, 0.0% of Proteome Sciences shares are owned by institutional investors. 8.0% of Abingdon Health shares are owned by company insiders. Comparatively, 36.7% of Proteome Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Abingdon Health has higher revenue and earnings than Proteome Sciences. Abingdon Health is trading at a lower price-to-earnings ratio than Proteome Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abingdon Health£9.57M2.63-£796.37K-£0.81N/A
Proteome Sciences£3.76M1.61-£4.08M-£1.04N/A

Summary

Abingdon Health beats Proteome Sciences on 8 of the 11 factors compared between the two stocks.

Get Abingdon Health News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABDX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ABDX vs. The Competition

Export
MetricAbingdon HealthLife Sciences Tools & Services IndustryHealthcare SectorLON Exchange
Market Cap£25.21M£9.56B£7.04B£2.88B
Dividend YieldN/A1.46%2.57%6.11%
P/E Ratio-12.4049.17214.69368.68
Price / Sales2.63105.71617.3583,339.32
Price / Cash2.2526.1175.7027.89
Price / Book13.8037.5012.927.18
Net Income-£796.37K£56.66B£3.45B£5.89B
7 Day Performance-4.38%0.29%1.16%0.91%
1 Month Performance2.97%1.38%1.37%2.94%
1 Year Performance57.44%17.34%62.53%64.32%

Abingdon Health Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ABDX
Abingdon Health
N/AGBX 10.04
-4.4%		N/A+62.2%£25.21M£9.57MN/A84
GDR
genedrive
N/AGBX 1.16
-3.3%		N/A+37.3%£18.63M£929KN/A43
YGEN
Yourgene Health
N/AN/AN/AN/A£16.43M£29.67MN/A253
AGL
ANGLE
N/AGBX 2.35
-11.3%		N/A-55.7%£7.58M£2.62MN/A650
GENI
GENinCode
N/AGBX 0.90
+5.9%		N/A-38.7%£6.78M£3.08MN/A2,300

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:ABDX) was last updated on 8/15/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel